| # | Drug | Count |
|---|---|---|
| 0 | EMPAGLIFLOZIN | 3903 |
| 1 | METFORMIN | 3617 |
| 2 | METFORMIN ER 500 MG | 3617 |
| 3 | METFORMIN ER 750 MG | 3617 |
| 4 | CANAGLIFLOZIN | 3441 |
| 5 | INSULIN GLARGINE | 2644 |
| 6 | INSULIN LISPRO | 1796 |
| 7 | DAPAGLIFLOZIN | 1648 |
| 8 | QUETIAPINE | 1437 |
| 9 | INSULIN ASPART | 1361 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CANAGLIFLOZIN | 3441 | 0.1152 |
| 1 | CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 163 | 0.0898 |
| 2 | EMPAGLIFLOZIN AND LINAGLIPTIN | 149 | 0.0758 |
| 3 | ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 6 | 0.0732 |
| 4 | EMPAGLIFLOZIN | 3903 | 0.0562 |
| 5 | EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE | 190 | 0.0533 |
| 6 | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 156 | 0.0529 |
| 7 | INAVOLISIB | 34 | 0.0507 |
| 8 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 177 | 0.0505 |
| 9 | ERTUGLIFLOZIN | 54 | 0.0484 |
| # | Drug class | Count |
|---|---|---|
| 0 | Insulin Analog [EPC] | 5752 |
| 1 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 5298 |
| 2 | GLP-1 Receptor Agonist [EPC] | 1777 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1353 |
| 4 | Corticosteroid [EPC] | 1276 |
| 5 | Atypical Antipsychotic [EPC] | 1126 |
| 6 | HMG-CoA Reductase Inhibitor [EPC] | 896 |
| 7 | Benzodiazepine [EPC] | 885 |
| 8 | Platelet Aggregation Inhibitor [EPC] | 791 |
| 9 | Proton Pump Inhibitor [EPC] | 755 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 5298 | 0.0486 |
| 1 | Dipeptidyl Peptidase 4 Inhibitor [EPC] | 553 | 0.0170 |
| 2 | alpha-Glucosidase Inhibitor [EPC] | 78 | 0.0160 |
| 3 | Farnesyltransferase Inhibitor [EPC] | 1 | 0.0128 |
| 4 | Insulin Analog [EPC] | 5752 | 0.0128 |
| 5 | Catecholamine Synthesis Inhibitor [EPC] | 1 | 0.0123 |
| 6 | Leptin Analog [EPC] | 15 | 0.0119 |
| 7 | Antihypoglycemic Agent [EPC] | 46 | 0.0107 |
| 8 | Insulin [EPC] | 488 | 0.0105 |
| 9 | CTLA-4-directed Blocking Antibody [EPC] | 421 | 0.0087 |